Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-H0731 in Healthy Volunteers and Chronic Hepatitis B
NCT02908191Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vebicorvir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Assembly Biosciences, Inc. Primary endpoint: Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events up to 57 days. Started Nov 2016; status: completed.
02
Drugs
vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02908191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908191.